Last $3.59 USD
Change Today +0.3783 / 11.78%
Volume 44.0K
As of 8:04 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

bacterin international holdi (BONE) Snapshot

Open
$3.15
Previous Close
$3.21
Day High
$3.75
Day Low
$3.15
52 Week High
03/20/14 - $14.10
52 Week Low
11/20/14 - $2.19
Market Cap
24.0M
Average Volume 10 Days
67.0K
EPS TTM
$-5.23
Shares Outstanding
6.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BACTERIN INTERNATIONAL HOLDI (BONE)

Related News

No related news articles were found.

bacterin international holdi (BONE) Related Businessweek News

No Related Businessweek News Found

bacterin international holdi (BONE) Details

Bacterin International Holdings, Inc. develops, manufactures, and markets biologics products in the United States and internationally. The company’s Biologics Division offers products that are used in various applications, including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing, neurosurgery, and subchondral bone repair. Its biologics products include OsteoSponge, which provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC, a subchondral bone void filler; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as is used in conjunction with a hardware plate system. This segment also provides OsteoLock and BacFast facet stabilization dowels that are used to augment spinal procedures; and hMatrix dermal scaffold, which promotes cellular ingrowth, tissue vascularization, and regeneration. In addition, Biologics Division manufactures and sells sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled allografts; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Bacterin International Holdings, Inc.’s Medical Devices division offers coatings for medical devices; OsteoSelect DBM putty, an osteoinductive and osteoconductive product used by surgeons as a bone void filler in the extremities and pelvis; and custom surgical instruments for use with allografts. This segment also sells Via and Elutia, surgical drain series products used to drain exudate from a surgical site. The company markets its products through direct sales, as well as through distributor relationships. Bacterin International Holdings, Inc. is headquartered in Belgrade, Montana.

128 Employees
Last Reported Date: 03/27/14
Founded in 2010

bacterin international holdi (BONE) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $143.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $422.3K
Chief Operating Officer
Total Annual Compensation: $338.6K
Chief Scientific Officer
Total Annual Compensation: $271.1K
Compensation as of Fiscal Year 2013.

bacterin international holdi (BONE) Key Developments

Bacterin International Holdings, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2014

Bacterin International Holdings, Inc. provided preliminary unaudited revenue guidance for the fourth quarter and full year of 2014. The company is expecting total revenue for the fourth quarter of 2014 to be in the range of $8.9 million to $9.1 million, representing an increase of approximately 8% to 10% when compared to $8.3 million reported for the fourth quarter of 2013. For the year, the company is expecting total revenues to be in the range of $35.2 million to $35.4 million, representing an increase of 6% to 7% compared to 2013 reported revenue of $33.1 million.

Bacterin International Holdings, Inc. Presents at LD Micro Conference, Dec-04-2014 01:30 PM

Bacterin International Holdings, Inc. Presents at LD Micro Conference, Dec-04-2014 01:30 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States. Speakers: John P. Gandolfo, Chief Financial Officer, Principal Accounting Officer, Treasurer and Secretary.

Bacterin International Holdings Receives Delisting Notice From NYSE MKT

Bacterin International Holdings, Inc. announced that the Company received notice that the staff of NYSE Regulation, Inc. has determined to commence proceedings to delist the Company's common stock from the NYSE MKT LLC ("NYSE MKT" or the "Exchange") because the Company did not cure its non-compliance with Sections 1003(a)(i), (ii) and (iii) of the NYSE MKT Company Guide by the end of the maximum 18 month compliance plan period, which expired on November 13, 2014. Therefore, the Company's common stock is subject to delisting from the Exchange. The Company plans to appeal the delisting determination. The Company's common stock will continue to trade on the NYSE MKT pending the appeal and final determination by the hearing panel.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BONE:US $3.59 USD +0.3783

BONE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biolase Inc $2.17 USD +0.12
Cardica Inc $0.63 USD +0.0523
Stereotaxis Inc $2.37 USD -0.06
Uroplasty Inc $1.22 USD 0.00
Vision Sciences Inc/DE $0.50 USD +0.0098
View Industry Companies
 

Industry Analysis

BONE

Industry Average

Valuation BONE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BACTERIN INTERNATIONAL HOLDI, please visit www.bacterin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.